NLRP3 antibody | knockout validation | Santa Cruz Biotechnology H66
DOI
//dx.doi.org/10.13070/ko.en.6.1743
Date
2016-10-18

This is a knockout-validated antibody summary, based on the publication "Increased VEGF‐A promotes multiple distinct aging diseases of the eye through shared pathomechanisms", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

NLRP3 antibody | knockout validation | Santa Cruz Biotechnology H66 figure 1
Figure 1. A) LRP3 is expressed in RPE cells at sites of choroidal neovascularization lesions (arrow; white). CD31(in red) is used as a blood vessel marker, and phalloidin (in green) to label the cytoskeleton. Scale bar, 100 μm. B) Lack of NLRP3 staining in VEGF‐Ahyper/Nlrp3−/− mice (control). Scale bar, 100 μm. From [1].
Antibody information

Rabbit polyclonal IgG

Company: Santa Cruz Biotechnology

Antibody: NLRP3

Catalog number: H66

Summary: Rabbit polyclonal IgG against an epitope corresponding to amino acids 25-90 mapping near the N-terminus of human cryopyrin. Recommended for the detection of cryopyrin in mouse, rat and human. Suitable for western blot, immunoprecipitation, immunofluorescence, immunohistochemistry (paraffin) and ELISA. Also reactive with additional species, including and equine, canine, bovine and porcine.

Validation Method

Immunofluorescence

Sample

VEGF‐Ahyper and VEGF‐Ahyper/Nlrp3−/− mice eyes.

Blocking agent

5% serum.

Primary incubation

1:50 dilution overnight at 4°C.

Secondary incubation

Alexa‐555, or Alexa‐647 antibodies (Life Technologies) at 1:100 dilution incubated for 3 h at room temperature in the dark.

Detection

Zeiss epifluorescence microscope (Carl Zeiss Microscopy, Jena, Germany) or Nikon confocal microscope (Nikon Instruments Inc, Melville, NY).

References
  1. Marneros A. Increased VEGF-A promotes multiple distinct aging diseases of the eye through shared pathomechanisms. EMBO Mol Med. 2016;8:208-31 pubmed publisher